Showing results (1241-1250 of 6,507) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|September 21, 2018
TIGIT: a novel immunotherapy target moving from bench to bedsideBenjamin L Solomon, Ignacio Garrido-LagunaCancer Immunology, Immunotherapy : CII|September 21, 2018
Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-upJeong-Hoon Lee, Joon Hyeok Lee, Young-Suk Lim, et al.Cancer Immunology, Immunotherapy : CII|June 22, 2019
The challenges of adoptive cell transfer in the treatment of human renal cell carcinomaZuzana Strizova, Jirina Bartunkova, Daniel SmrzCancer Immunology, Immunotherapy : CII|June 22, 2019
Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1)Despoina Koumantou, Eilon Barnea, Adrian Martin-Esteban, et al.Cancer Immunology, Immunotherapy : CII|July 7, 2019
Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cellsZhengyuan Li, Yiqing Wu, Chao Wang, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1988
Role of proliferation in LAK cell developmentF J Ramsdell, H Shau, S H GolubCancer Immunology, Immunotherapy : CII|April 6, 2023
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigatingYize Mao, Hui Xie, Minyi Lv, et al.Cancer Immunology, Immunotherapy : CII|April 11, 2023
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cellsAnetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, et al.Cancer Immunology, Immunotherapy : CII|April 20, 2023
Massively recruited sTLR9+ neutrophils in rapidly formed nodules at the site of tumor cell inoculation and their contribution to a pro-tumor microenvironmentMengyuan Kou, Wenting Lu, Mengru Zhu, et al.Cancer Immunology, Immunotherapy : CII|April 12, 2023
BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trialsKan Liu, Yan Huang, Yu Xu, et al.Pageof 651